Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 7/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.65 |
| ▸ | PGR | P06401 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL6 | P05231 | 1/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.65 |
| ▸ | GLUL | P15104 | 1/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142733 | 0.99 | NR3C2 (0.74) | NR3C2HIF1AKMT2ANR3C1PGR | |
| SCHEMBL7613014 | 0.99 | NR3C2 (0.74) | NR3C2HIF1AKMT2ANR3C1PGR | |
| SCHEMBL7145314 | 0.99 | NR3C2 (0.74) | NR3C2HIF1AKMT2ANR3C1PGR | |
| Prednival SCHEMBL11585728 | 0.98 | HIF1A (0.73) | NR3C2HIF1AKMT2ANR3C1PGR | |
| Prednival SCHEMBL2966212 | 0.98 | HIF1A (0.73) | NR3C2HIF1AKMT2ANR3C1PGR | |
| Prednival SCHEMBL25388 | 0.98 | HIF1A (0.73) | NR3C2HIF1AKMT2ANR3C1PGR | |
| Prednival SCHEMBL2966209 | 0.98 | HIF1A (0.73) | NR3C2HIF1AKMT2ANR3C1PGR | |
| Prednival SCHEMBL25387 | 0.98 | HIF1A (0.73) | NR3C2HIF1AKMT2ANR3C1PGR | |
| SCHEMBL11016342 | 0.94 | NR3C2 (0.72) | NR3C2HIF1AKMT2ANR3C1PGR | |
| SCHEMBL6857090 | 0.94 | NR3C2 (0.72) | NR3C2HIF1AKMT2ANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1447804-A | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS INC (US) | 2003-10-08 | — | — | CN | claimed |
| CN-119012999-A | Improved nasal administration of pharmaceutical formulations | 思瑞诺医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11858951-B2 | Boronic acid derivatives | MERCK PATENT GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| WO-2023232830-A1 | BORONIC ACID ADDUCTS | MERCK PATENT GMBH (DE) | 2023-12-07 | — | — | WO | disclosed |
| US-20230390270-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2023-12-07 | — | — | US | disclosed |
| EP-3826723-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-10-18 | — | — | EP | disclosed |
| EP-4199927-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | Biogen MA Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| CN-111183142-B | Boric acid derivatives | 默克专利股份公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116096421-A | Methods for treating remission-type multiple sclerosis | 渤健马萨诸塞州股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3672977-B1 | BORONIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-06-22 | — | — | EP | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010091996-A1 | 2-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010069949-A1 | OXADIAZOLE FUSED HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS | MERCK SERONO S.A. (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010037765-A2 | 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES | MERCK SERONO S.A. (CH) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| CN-100490915-C | Otolaryngological delivery device | SCHERING OY (FI) | 2009-05-27 | — | — | CN | disclosed |
| CN-1767870-A | Otorhinology dosing device | TIMO HAAPAKUMPU HARRI JUKARA J (FI) | 2006-05-03 | — | — | CN | disclosed |
| CN-1596240-A | Chalcone derivatives and their use for the treatment of diseases | ATHEROGENICS INC (US) | 2005-03-16 | — | — | CN | disclosed |
| CN-1447804-A | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders | ATHEROGENICS INC (US) | 2003-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390270-A1 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | SGMS1, SGMS2, HMGCR | NR3C2 603/4885HIF1A 4216/4885KMT2A 2171/4885 |
| US-11858951-B2 | Boronic acid derivatives | PSMB7, PSMA7, BRD7 | NR3C2 3914/4885HIF1A 879/4885KMT2A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.